| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
6,994 |
6,586 |
$888K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,264 |
5,887 |
$212K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,798 |
6,316 |
$197K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
673 |
642 |
$87K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,986 |
649 |
$54K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,618 |
1,538 |
$41K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
654 |
291 |
$18K |
| 81007 |
|
928 |
835 |
$13K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
149 |
145 |
$11K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
184 |
174 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
123 |
122 |
$6K |
| 95921 |
|
238 |
216 |
$5K |
| 86328 |
|
148 |
145 |
$4K |
| 99000 |
|
325 |
300 |
$3K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
144 |
141 |
$3K |
| 95923 |
|
222 |
202 |
$2K |
| 97161 |
|
15 |
14 |
$1K |
| 99402 |
|
108 |
92 |
$1K |
| 87425 |
|
124 |
123 |
$1K |
| 97162 |
|
35 |
34 |
$589.91 |
| 76942 |
|
14 |
14 |
$545.28 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
211 |
93 |
$461.05 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
57 |
57 |
$434.14 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
20 |
18 |
$395.74 |
| 84403 |
|
60 |
60 |
$384.08 |
| 84443 |
Thyroid stimulating hormone (TSH) |
61 |
61 |
$238.17 |
| 99407 |
|
107 |
73 |
$229.22 |
| 84439 |
|
47 |
47 |
$62.34 |
| 84153 |
|
16 |
16 |
$42.38 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
245 |
82 |
$9.77 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
544 |
499 |
$0.00 |
| 99072 |
|
156 |
132 |
$0.00 |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
55 |
55 |
$0.00 |
| 95816 |
|
17 |
17 |
$0.00 |
| 95831 |
|
84 |
62 |
$0.00 |
| 97032 |
|
31 |
12 |
$0.00 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
73 |
29 |
$0.00 |
| 20553 |
|
14 |
14 |
$0.00 |